The effect of intragastric balloon on serum lipids level in patients with morbid obesity;Wpływ leczenia balonem wewnatrz-żoładkowym na steżenie lipidów w surowicy u pacjentów z otyłościa olbrzymia

Polski Merkuriusz Lekarski

Volumn 26, Issue 155, 2009, Pages 430-434

  Konopko Zubrzycka, M ^a,c   Kowalska, I ^b,d   Wroblewski E ^a,c   Baniukiewicz, A ^a,c   Zarzycki, W ^b,d   Gorska M ^b,d   Dabrowski, A ^a,c  

^a Laboratory of Flowcytometry   (Poland)

^b Klinika Endokrynologii   (Poland)

^c Department of Gastroenterology and Internal Diseases ^*  (Poland)

^d Diabetology and Internal Diseases   (Poland)

Author keywords

Intragastric balloon; Obesity; Serum lipids

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BALLOON DILATATION; BARIATRICS; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MORBID OBESITY; NAUSEA; VOMITING;

ADULT; BALLOON DILATATION; BARIATRICS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; OBESITY, MORBID; TRIGLYCERIDES; VOMITING; YOUNG ADULT;

EID: 67949117256     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Abell TL., Minocha A.: Gastrointestinal complications of bahatric surgery: diagnosis and therapy. Am J Med Sci., 2006, 331(4), 214-218.
2. Bralin RE., Bradley LJ., Wilson AC. i wsp.: Lipid risk profile and weight stability after gastrin restrictive operations for morbid obesity. J Gastroin-test Surg. 2000, 4(5), 464-469.
3. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM., Blac-kwell L., Collins R., i wsp.: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomized trials of statins: a metaanalysis. Lancet. 2008, 12, 371, 117-125.
4. Corradini SG., Eramo A., Lubrano C. i wsp.: Comparison of changes in lipid profile after bilio-intestinal bypass and gastric banding in patients with morbid obesity. Obes Surg. 2005,15(3), 367-377.
5. Dobrea GM., Wieland RG., Johnson MW. The effect of rapid weight loss due to jejunoileal bypass on total cholesterol and high-density lipoprotein. Am J Clin Nutr. 1981,34(10),1994-1996.
6. Durrans D., Taylor TV.: Comparison of weight loss with short term dietary and intragastric balloon treatment. Gut 1989, 30(5), 565-568.
7. Evans JD., Scott MH. Intragastric balloon in the treatment of patients with morbid obesity. Br J Surg 2001, 88(9), 1245-1248.
8. Ford E.S., Giles WH., Dietz WH.: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287, 356-359.
9. Genco A., Bruni T., Doldi SB., i wsp. Bioȩnterics Intragastric Balloon: The Italian Experience with2,515Patients. Obes Surg., 2005, 15(8), 1161-1164.
10. Gonen B., Halverson JD., Schonfeld G: Lipoprotein levels in morbidly obese patients with massive, surgically-induced weight loss. Metabolism. 1983, 32(5), 492-496.
11. Herve J., Wahlen CH., Schaeken A., i wsp.: What becomes of patients one year after the intragastric balloon has been removed? Obes Surg 2005, 15(6), 864-870.
12. Isomaa B., Almgren P., Tuomi X, i wsp.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24(4), 683-689.
13. Lewis S., Haskell WL, Wood PD., i wsp.: Effects of physical activity on weight reduction in obese middle-aged women. Am J Clin Nutr. 1976, 29(2), 151-156.
14. Loffredo A., Cappuccio M., De Luca M., i wsp.: Three years experience with the new intragastric balloon, and a preoperative test for success with restrictive surgery. Obes Surg. 2001, 11(3), 330-333.
15. Lubrano C, Cornoldi A., Pili M. i wsp.: Reduction of risk factors for cardiovascular diseases in mortiid-obese patients following biliary-intestinal bypass: 3 years' follow-up. Int J Obes Relat Metab Disord. 2004, 28(12),1600-1606.
16. Mango VL, Frishman WH.: Physiologic, psychologic, and metabolic consequences of bariatric surgery. Cardiol Rev., 2006, 14(5), 232-237.
17. Mayers CD., Kashyap ML. Pharmacologic elevation of high-density lipoproteins: recent insight on mechanisms of action and artheriosclerosis protection. Curr Opin Cardiol, 2004; 19: 366-373.
18. National Heart, Lung, and Blood Institute (NHLBI)and National Institute for Diabetes and Digestive and Kidney Diseases (NIDDKD). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report. Obes Res 1998,6 (Suppl 2), 51S-210S.
19. Nguyen NT, Varela E, Sabio A, i wsp.: Resolution of hyperlipidemia after laparoscopic Roux-en-Y gastric bypass. J Am Coll Surg., 2006, 203(1), 24-29.
20. Schauer PR., Burguera B., Ikramuddin S., i wsp.: Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg., 2003, 238, 467-484.
21. Third report of the Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): executive summery. Available at:www.nhlbi.nih.gov/guidelines/cholesterol/ atp3xsum.pdf.
22. Thompson PD., Jeffery RW., Wing RR., i wsp.: Unexpected decrease in plasma high density lipoprotein cholesterol with weight loss. Am J Clin Nutr. 1979, 32(10), 2016-2021.
23. Tottś E., Hendrickx L., Pauwels M., i wsp.: Weight reduction by means of intragastric device: experience with the bioenterics intragastric balloon. Obes Surg. 2001, 11(4), 519-523.
24. Trayhum P., Wood I.S.,: Adipokines.lnflammation and the pleiotropic role of wihite adipose tissuea. Br.J.Nutr. 2004, 92, 347-355.
25. Williams DB., Hagedorn JC, Lawson EH., Galanko JA., i wsp.: Gastric bypass reduces biochemical cardiac risk factors. Surg Obes Relat Dis. 2007, 3(1), 8-13.